NVNO Quote, Financials, Valuation and Earnings

NeuroOne Medical Technologies has a net margin of -- compared to enVVeno Medical's net margin of -1230.55%. enVVeno Medical's return on equity of -- beat NeuroOne Medical Technologies's return on equity of -335.54%.

enVVeno Medical has a consensus price target of --, signalling upside risk potential of 471.43%. On the other hand NeuroOne Medical Technologies has an analysts' consensus of -- which suggests that it could grow by 144.56%. Given that enVVeno Medical has higher upside potential than NeuroOne Medical Technologies, analysts believe enVVeno Medical is more attractive than NeuroOne Medical Technologies.

enVVeno Medical has a beta of 1.219, which suggesting that the stock is 21.904% more volatile than S&P 500. In comparison NeuroOne Medical Technologies has a beta of 0.688, suggesting its less volatile than the S&P 500 by 31.224%.

enVVeno Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroOne Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. enVVeno Medical pays -- of its earnings as a dividend. NeuroOne Medical Technologies pays out -- of its earnings as a dividend.

enVVeno Medical quarterly revenues are --, which are smaller than NeuroOne Medical Technologies quarterly revenues of $272.3K. enVVeno Medical's net income of -$5.6M is lower than NeuroOne Medical Technologies's net income of -$3.4M. Notably, enVVeno Medical's price-to-earnings ratio is -- while NeuroOne Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for enVVeno Medical is 268.65x versus 6.34x for NeuroOne Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband has a net margin of -- compared to enVVeno Medical's net margin of -211%. enVVeno Medical's return on equity of -- beat Nutriband's return on equity of -69.58%.

enVVeno Medical has a consensus price target of --, signalling upside risk potential of 471.43%. On the other hand Nutriband has an analysts' consensus of -- which suggests that it could grow by 367.53%. Given that enVVeno Medical has higher upside potential than Nutriband, analysts believe enVVeno Medical is more attractive than Nutriband.

enVVeno Medical has a beta of 1.219, which suggesting that the stock is 21.904% more volatile than S&P 500. In comparison Nutriband has a beta of 0.358, suggesting its less volatile than the S&P 500 by 64.193%.

enVVeno Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. enVVeno Medical pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.

enVVeno Medical quarterly revenues are --, which are smaller than Nutriband quarterly revenues of $645.8K. enVVeno Medical's net income of -$5.6M is lower than Nutriband's net income of -$1.4M. Notably, enVVeno Medical's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for enVVeno Medical is 268.65x versus 18.87x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.

SINTX Technologies has a net margin of -- compared to enVVeno Medical's net margin of -1700%. enVVeno Medical's return on equity of -- beat SINTX Technologies's return on equity of -132.95%.

enVVeno Medical has a consensus price target of --, signalling upside risk potential of 471.43%. On the other hand SINTX Technologies has an analysts' consensus of -- which suggests that it could grow by 1751.85%. Given that SINTX Technologies has higher upside potential than enVVeno Medical, analysts believe SINTX Technologies is more attractive than enVVeno Medical.

enVVeno Medical has a beta of 1.219, which suggesting that the stock is 21.904% more volatile than S&P 500. In comparison SINTX Technologies has a beta of 1.497, suggesting its more volatile than the S&P 500 by 49.673%.

enVVeno Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. enVVeno Medical pays -- of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend.

enVVeno Medical quarterly revenues are --, which are smaller than SINTX Technologies quarterly revenues of $367K. enVVeno Medical's net income of -$5.6M is higher than SINTX Technologies's net income of -$6.2M. Notably, enVVeno Medical's price-to-earnings ratio is -- while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for enVVeno Medical is 268.65x versus 1.04x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Beyond Air has a net margin of -- compared to enVVeno Medical's net margin of -1673.94%. enVVeno Medical's return on equity of -- beat Beyond Air's return on equity of -219.34%.

enVVeno Medical has a consensus price target of --, signalling upside risk potential of 471.43%. On the other hand Beyond Air has an analysts' consensus of -- which suggests that it could grow by 468.18%. Given that enVVeno Medical has higher upside potential than Beyond Air, analysts believe enVVeno Medical is more attractive than Beyond Air.

enVVeno Medical has a beta of 1.219, which suggesting that the stock is 21.904% more volatile than S&P 500. In comparison Beyond Air has a beta of -0.225, suggesting its less volatile than the S&P 500 by 122.529%.

enVVeno Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beyond Air offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. enVVeno Medical pays -- of its earnings as a dividend. Beyond Air pays out -- of its earnings as a dividend.

enVVeno Medical quarterly revenues are --, which are smaller than Beyond Air quarterly revenues of $798K. enVVeno Medical's net income of -$5.6M is higher than Beyond Air's net income of -$13.4M. Notably, enVVeno Medical's price-to-earnings ratio is -- while Beyond Air's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for enVVeno Medical is 268.65x versus 7.63x for Beyond Air. Usually stocks with elevated PS ratios are considered overvalued.